| (Values in U.S. Thousands) | Sep, 2022 | Jun, 2022 | Mar, 2022 | Dec, 2021 | Sep, 2021 |
| Sales | 9,830 | 8,210 | 6,830 | 32,520 | 3,660 |
| Sales Growth | +19.73% | +20.21% | -79.00% | +788.52% | +50.62% |
| Net Income | -37,800 | -39,950 | -42,430 | -10,960 | 57,090 |
| Net Income Growth | +5.38% | +5.84% | -287.14% | -119.20% | +256.75% |
Albireo Pharma Inc (ALBO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States.
Fiscal Year End Date: 12/31